|Articles|November 15, 2018
- Pharmaceutical Technology-11-15-2018
- Volume 2018 eBook
- Issue 2
Multiple Attributes Monitoring: A New Phase in PAT for Biopharmaceuticals
Author(s)Agnes Shanley
By reducing the number of assays needed and allowing product quality attributes to be measured end to end, MAM promises to allow users to gain product and process understanding much sooner than they could in the past, and to ensure quality and safety in a more efficient, streamlined way, throughout the product life cycle.
Advertisement
Interest is growing in a new approach that allows the monitoring of critical quality attributes in real time for complex biologics such as monoclonal antibodies, opening up new possibilities in biopharmaceutical development and quality control. A consortium of biopharmaceutical companies, analytical instrumentation vendors, FDA and NIST is exploring capabilities and promoting this approach.
Article Details
Pharmaceutical Technology
eBook: Bio/Pharma Laboratory Best Practices 2018
Vol. 42
November 2018
Pages: 14–15
Citation
When referring to this article, please cite it as A. Shanley, "Multiple Attributes Monitoring: A New Phase in PAT for Biopharmaceuticals," Pharmaceutical Technology Bio/Pharma Laboratory Best Practices eBook (November 2018).
Articles in this issue
almost 7 years ago
Precompetitive Research Spurs Innovation in Pharmaceutical Analysisalmost 7 years ago
Cobots in the Pharma Labalmost 7 years ago
Analytical Best Practices for Raw Materials Testingalmost 7 years ago
Complex Protein Studies Demand Dynamic Techniquesalmost 7 years ago
Barriers and Solutions to Effective External Collaboration in Biopharmaalmost 7 years ago
Best Practices in Analytical Method Development and Testingalmost 7 years ago
Mixed Reality Gains a Foothold in the LabNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
UK’s Persistent Failure to Commercialize R&D Threatens Life Sciences: Report
2
BBB-Crossing Tech for Lysosomal Storage Disorders at Center of Chiesi–Aliada Partnership
3
Share Your Perspective on the Commissioner’s National Priority Vouchers Program
4
PharmTech Weekly News Roundup — Week of November 10, 2025
5
